A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
ConditionHuntington's Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age25-70
SponsorAlnylam Pharmaceuticals
About this trial
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Eligibility criteria
Qualifiers
Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS)
Disqualifiers
Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening
Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies
Has alanine aminotransferase or aspartate aminotransferase >2× upper limit of normal (ULN)
Has an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m² at screening
Trial design
Treatments tested in this trial
- ALN-HTT02
- Placebo
Treatment groups
66 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov